DexCom Q2 2026 revenue up 13% to $1.308B; raises FY2026 guidance

DEXCOM INC

Revenue $1.308B (+13% YoY); U.S. +11%, international +19% reported.
GAAP EPS $0.64; non-GAAP EPS $0.70; GAAP operating margin 24.3% (+590 bps YoY).
Raises FY2026 revenue guidance to $5.18-5.25B (11-13% growth); raises non-GAAP operating margin to ~23.5-24%.
CONNECT trial shows CGM improves glucose control in type 2 diabetes not on insulin; Stelo app launched with AI insights.
Cash $1.95B; revolving credit undrawn.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.